April 2017 in “Journal of Investigative Dermatology” In this study, HPH-15, a newly synthesized compound, demonstrated potential in reducing skin fibrosis in a mouse model by targeting underlying pathogenic mechanisms and exhibited a good safety profile, warranting further clinical trials for fibrotic skin disorders like systemic sclerosis.
May 2026 in “Cell Reports Medicine” This study develops FR-1, a topical small molecule, which reduces scarring and avoids skin atrophy in a murine wound model, showing potential for treating fibrosis without the side effects of current therapies.
April 2019 in “Journal of Investigative Dermatology” This study found that CYP11A1-derived vitamin D3 analogs inhibit fibroblast proliferation and decrease collagen production through VDR expression, showing potential antifibrotic and antiproliferative activity in human dermal fibroblasts.
April 2023 in “Journal of Investigative Dermatology” In this study, recombinant type III collagen was found to promote fibroblast proliferation and migration, suggesting potential anti-aging and repairing effects, although it was only effective in significantly inhibiting IL-6, not TNF-α, secretion.
6 citations
,
August 2024 in “Biomacromolecules” This study introduces a novel in vitro model for clubfoot fibrosis to enable high-throughput drug screening and found that while the model increased collagen deposition, the antifibrotic drug minoxidil effectively inhibited the expression of collagen cross-linking enzymes.